DOT-HDC-Header

Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) currently being tested in preclinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that can cause adverse cellular effects and unwanted toxicity. Cambridge Healthtech Institute’s ninth annual event on Next Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family. The interactive sessions and panel discussions are all geared to provide ample opportunity for active networking, brainstorming and collaborating.

Who should attend: Students, Post-Docs, Lab Technicians, Managers, Scientists, Clinicians, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in Drug Discovery of Epigenetic Targets, Functional Screening, Compound Screening, Target ID and Validation, Biomarker Discovery, and Translational Research.

Topics will include, but are not limited to: 

  • New HDAC chemistries
  • Exploring HDAC biology using chemical probes, imaging and more
  • Using structural biology to guide chemical design
  • Screening HDAC inhibitors: Use of animal models and in vitro assays
  • Evaluating the use of pan versus isoform-specific inhibitors
  • Update on novel HDACi; preclinical and clinical progress update

If you are interested in speaking, click here to submit a speaking proposal.

The deadline for submission is March 11, 2015. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon 

2014 Discovery on Target Brochure  

2014 BROCHURE 

PREMIER SPONSOR 

Cellecta 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000